AbbVie (ABBV) is expected to reiterate its fiscal 2025 guidance, but there could be potential risk in its aesthetics business line, UBS said in a note Friday.
The analysts said that this quarter will "set the tone for consumer sentiment and growth of Aesthetics for the year." With the guidance premised on gradual improvement in market growth, they said that uncertainty in the current macro environment could present a risk.
In particular, they cited the tariffs on China impacting the company's aesthetics products, which could hinder growth in markets outside the US.
UBS lowered its 2025 revenue forecast for the company to $59.2 billion from $59.5 and earnings to $12.08 per share from $12.28 per share.
The brokerage has a neutral rating for AbbVie with a $190 price target.
Price: 175.67, Change: +1.47, Percent Change: +0.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.